Pharmacokinetic-Pharmacodynamic Modeling of a Direct Thrombin Inhibitor, Argatroban, in Rats |
Park, Eun-Hye
(Korea Food & Drug Administration)
Shin, Beom-Soo (College of Pharmacy, Catholic University of Daegu) Yun, Chi-Ho (Choongwae Pharm. Co.) Lee, Mann-Hyung (College of Pharmacy, Catholic University of Daegu) Yoo, Sun-Dong (College of Pharmacy, Sungkyunkwan University) |
1 | T. Tamao, T. Yamamoto, T. Hirata, M. Kinusaga and R. Kikumoto, Effect of argatroban on blood coagulation, Jap. J. Pharm. Ther., 14, 7-12 (1986). |
2 | K. McKeage and G.L. Plosker, Argatroban, Drugs, 61, 515-522 (2001). DOI ScienceOn |
3 | S. Ahmad, A. Ahsan, M. George, O. Iqbal, W.P. Jeske, R. McKenna, B.E. Lewis, J.M. Walenga and J. Fareed, Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications, Clin. Appl. Thromb. Hemost., 5, 252-258 (1999). DOI |
4 | W. Jeske, J.M. Walenga, B.E. Lewis and J. Fareed, Pharmacology of argatroban, Expert Opin. Invest. Drugs, 8, 625-654 (1999). DOI ScienceOn |
5 | D. Callas and J. Fareed, Comparative pharmacology of site directed antithrombin agents. Implication in drug development, Thromb. Haemost., 74, 473-481 (1995). |
6 | R. Nagashima, R.A. O'Reilly and G. Levy, Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin, Clin. Pharmacol. Ther., 10, 22-35 (1969). DOI |
7 | J. Hauptmann, Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors, Eur. J. Clin. Pharmacol., 57, 751-758 (2002). |
8 | R. Stenz and K.H. Bauer, A new physiologically approached in vitro test for quick evaluation of the hemolytic activity of surfactants, Pharmazie, 51, 283-287 (1996). |
9 | K.W. Reed and S.H. Yalkowsky, Lysis of human red blood cells in the presence of various cosolvents, J. Parenter. Sci. Technol., 39, 64-69 (1985). |
10 | F. Mottu, A. Laurent, D.A. Rufenacht and E. Doelker, Organic solvents for pharmaceutical parenterals and embolic liquids, PDA J. Pharm. Sci. Technol., 54, 456-469 (2000). |
11 | S. Ahmad, L.H. Yang, A. Ahsan, K. Fu, O. Iqbal, D.A. Hoppensteadt, B.E. Lewis, J.M. Walenga and J. Fareed, Pharmacokinetics of argatroban in primates: evidence on endogenous uptake, Int. Angiol.. 19, 126-34 (2000). |
12 | C.N. Berry, C. Lunven, C. Lecoffre, P. Lainee, S.E. O'Connor, F. Andre, B. Roger, D. Garrigou-Gadenne, A. Rouchouse, N.O. Roome and N. Vivan, Anticoagulant activity and pharmacokinetic properties of a sub-cutaneously administered mixed micellar formulation of argatroban in experimental animals, Thromb. Haemost., 84, 278-285 (2000). |
13 | N. Duval, C. Lunven, D.P. O'Brien, A. Grosset, S.E. O'Connor and C.N. Berry, Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin, Br. J. Pharmacol., 118, 727-733 (1996). DOI ScienceOn |
14 | L.R. Bush, Argatroban, a selective, potent thrombin inhibitor, Cardiovas. Drug Rev., 9, 247-263 (1991). DOI |
15 | S.K. Swan and M.J. Hursting, The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction, Pharmacotherapy, 20, 318-329 (2000). DOI ScienceOn |
16 | W.J. Husa and J.R. Adams, Isotonic solutions. II. The permeability of red corpuscles to various substances, J. Am. Pharm. Assoc. Sci. Ed., 33, 329 (1944). DOI |